# OnCo record nobo-medicine (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/nobo-medicine/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "nobo-medicine" ;
  schema:name "NOBO Medicine"@en ;
  schema:alternateName "NOBO Medicine, Inc."@en, "Genome Opinion"@en, "노보메디슨"@en ;
  schema:description "NOBO Medicine develops treatments for blood cancers and inflammatory diseases linked to ageing of the immune system. Its cancer medicine, poseltinib, a drug that blocks the BTK protein, is in an early trial in Korea for non-Hodgkin lymphoma that has come back or not responded to treatment."@en ;
  schema:url <https://onco.cc/companies/nobo-medicine/>, <https://www.nobomedicine.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.nobomedicine.com/>, <http://en.nobomedicine.com/?research=history>, <https://clinicaltrials.gov/study/NCT07114367>, <https://clinicaltrials.gov/study/NCT06737250> ;
  schema:addressCountry "KR" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> .